In mouse models of RA with Clobenpropit treatment, the marked reduction in disease progression suggests using Clobenpropit-like molecules to target CXCR4 as a potential therapeutic strategy for arthritic conditions (Bekaddour et al., 2023). The gene discussed is CXCR4; the disease is rheumatoid arthritis.